Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. Headquartered in San Diego, California, the company's commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Acadia primarily operates in the United States, targeting underserved patient populations with specialized neurological needs.
ACADIA does not have a share repurchase or buyback program. As a growth-stage commercial biopharmaceutical company, it reinvests cash flow into its commercial franchises (NUPLAZID and DAYBUE), its clinical pipeline, and business development, and its 10-K for the year ended December 31, 2025 discloses no stock repurchase authorization or activity. The company ended 2025 with roughly $820 million in cash and investments (rising to $956 million by the end of Q2 2026).
ACADIA sells NUPLAZID to a limited number of specialty pharmacies and specialty distributors and sells DAYBUE in the U.S. through a single wholesale distributor with specialty-pharmacy service. For the year ended December 31, 2025, four such customers, each based in the United States, accounted for approximately 79% of NUPLAZID product revenue and 44% of total product revenue, creating meaningful customer concentration. The company does not own manufacturing facilities and relies on an outsourced manufacturing strategy for both NUPLAZID and DAYBUE.